Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy-Reference-Cited by-同舟云学术

Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy

Published:2017-03-18 Issue:10 Volume:52 Page:1122-1129
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Suda Goki, ,Ogawa Koji,Yamamoto Yoshiya,Katagiri Masaki,Furuya Ken,Kumagai Kenichi,Konno Jun,Kimura Megumi,Kawagishi Naoki,Ohara Masatsugu,Umemura Machiko,Ito Jun,Izumi Takaaki,Nakai Masato,Sho Takuya,Natsuizaka Mitsuteru,Morikawa Kenichi,Tsubota Akihito,Shimada Noritomo,Iio Etsuko,Tanaka Yasuhito,Sakamoto Naoya

Funder

Japan Agency for Medical Research and Development (JP)

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/article/10.1007/s00535-017-1328-z/fulltext.html

Reference27 articles.

1. Suda G, Kudo M, Nagasaka A, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016;1(7):733–40.

2. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645–53.

3. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083–91.